Home
TPST
TPST News

Latest Tempest Therapeutics Inc. (TPST) News on February 23, 2025

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

GlobeNewswire

13 days ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

15 days ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

GlobeNewswire

2 months ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

A ‘Reverse Aging’ Guru’s Trail of Failed Businesses

The Wall Street Journal

3 months ago

A ‘Reverse Aging’ Guru’s Trail of Failed Businesses

Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock

Simply Wall St.

3 months ago

Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

3 months ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

3 months ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

GlobeNewswire

3 months ago

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

GlobeNewswire

4 months ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Extends Limited Duration Stockholder Rights Plan

GlobeNewswire

4 months ago

Tempest Extends Limited Duration Stockholder Rights Plan

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

GlobeNewswire

5 months ago

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

6 months ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

GlobeNewswire

6 months ago

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

GlobeNewswire

6 months ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Argus Research

7 months ago

Daily – Vickers Top Buyers & Sellers for 07/09/2024

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 07/05/2024

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 07/03/2024

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

GlobeNewswire

8 months ago

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

GlobeNewswire

8 months ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest to Participate in Upcoming Investor Conferences

GlobeNewswire

9 months ago

Tempest to Participate in Upcoming Investor Conferences

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

GlobeNewswire

10 months ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

GlobeNewswire

a year ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

GlobeNewswire

a year ago

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

GlobeNewswire

a year ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest to Present at the 44th Annual TD Cowen Healthcare Conference

GlobeNewswire

a year ago

Tempest to Present at the 44th Annual TD Cowen Healthcare Conference

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

HMN Financial Inc. Reports Decreased Earnings in Q4 and Full Year 2023, Declares Dividend

GuruFocus.com

a year ago

HMN Financial Inc. Reports Decreased Earnings in Q4 and Full Year 2023, Declares Dividend

Health Care Roundup: Market Talk

The Wall Street Journal

a year ago

Health Care Roundup: Market Talk

Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH

Business Wire

a year ago

Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH

Business Wire

a year ago

First Trust Energy Infrastructure Fund Declares its Monthly Common Share Distribution of $0.10 Per Share for January

David Nierenberg Increases Stake in Flotek Industries Inc

GuruFocus.com

a year ago

David Nierenberg Increases Stake in Flotek Industries Inc

Associated Press Finance

a year ago

Conn's: Fiscal Q3 Earnings Snapshot

Conn’s, Inc. Reports Third Quarter Fiscal Year 2024 Financial Results

GlobeNewswire

a year ago

Conn’s, Inc. Reports Third Quarter Fiscal Year 2024 Financial Results

First Trust Energy Infrastructure Fund Issues Notice Regarding December 2023 Distribution

Business Wire

a year ago

First Trust Energy Infrastructure Fund Issues Notice Regarding December 2023 Distribution

5 Under-$15 Stocks Wall Street Analysts Recommend Buying

Zacks

a year ago

5 Under-$15 Stocks Wall Street Analysts Recommend Buying

Alto Ingredients, Inc. Publishes Sustainability Summary

GlobeNewswire

a year ago

Alto Ingredients, Inc. Publishes Sustainability Summary

Is It Smart To Buy First Capital, Inc. (NASDAQ:FCAP) Before It Goes Ex-Dividend?

Simply Wall St.

a year ago

Is It Smart To Buy First Capital, Inc. (NASDAQ:FCAP) Before It Goes Ex-Dividend?

Associated Press Finance

a year ago

Urban One: Q2 Earnings Snapshot

Associated Press Finance

a year ago

Urban One: Q1 Earnings Snapshot

ACCO Brands Corporation Announces Appointment of Beth Simermeyer to Board of Directors

Business Wire

a year ago

ACCO Brands Corporation Announces Appointment of Beth Simermeyer to Board of Directors

Associated Press Finance

a year ago

Urban One: Q3 Earnings Snapshot

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

GlobeNewswire

a year ago

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

PR Newswire

a year ago

VIRGINIA NATIONAL BANKSHARES CORPORATION ANNOUNCES QUARTERLY CASH DIVIDEND

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire

a year ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

GlobeNewswire

a year ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Digital Turbine, Inc. (NASDAQ:APPS) Q2 2024 Earnings Call Transcript

Insider Monkey

a year ago

Digital Turbine, Inc. (NASDAQ:APPS) Q2 2024 Earnings Call Transcript

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

ARC Document Solutions, Inc. (NYSE:ARC) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

ARC Document Solutions, Inc. (NYSE:ARC) Q3 2023 Earnings Call Transcript

Nautilus Biotechnology Reports Third Quarter 2023 Financial Results

GlobeNewswire

a year ago

Nautilus Biotechnology Reports Third Quarter 2023 Financial Results

Share on Social Networks: